Scientists at Eisai, a Japanese pharmaceutical company, have published research in the New England Journal of Medicine showing a potential Alzheimer’s drug that could usher in a new era of discovery and lead to improved drugs to treat the disease. Lecanemab, the new drug, is designed for those still in the early stages of the disease and works to destroy the beta-amyloid protein which builds up in the brains of Alzheimer’s patients. Compared to current Alzheimer’s drugs, Lecanemab influences the course of the disease rather than just treating its symptoms.
(Sources: BBC News, Time Magazine)
Leave a Reply